Calidi Biotherapeutics, Inc., a clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, today announced the acceptance of an abstract for presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium, which is being held February 6 to February 8, 2020, at the Rosen Shingle Creek Resort in Orlando, Florida.
“We look forward to sharing our data evidencing the ability of Calidi’s proprietary cell-based delivery platform to address a major obstacle in oncolytic virotherapy – the quick elimination of oncolytic viruses by the patient’s immune system,” said Boris Minev, MD, President, Medical and Scientific Affairs, Calidi Biotherapeutics. “Calidi’s platform not only protects, amplifies, and delivers the oncolytic viruses, but it also modifies the tumor microenvironment and activates the immune system to actively seek, and destroy distant tumor sites.”
ASCO-SITC Presentation Details Are As Follows:
Board C3
Abstract 21: A cell-based platform to potentiate oncolytic virus therapies.
Date: Thursday, February 6, from 11:30 AM - 1:00 PM and 6:00 PM - 7:00 PM
Location: Rosen Shingle Creek, Orlando, FL
Key Words: oncolytic virus, cancer, cancer therapies, cell-based delivery platform
About Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage immuno-oncology company with proprietary technology that is revolutionizing the effective delivery of oncolytic viruses for targeted therapy against difficult to treat cancers. Calidi Biotherapeutics is advancing a potent allogeneic stem cell and oncolytic virus combination for use in multiple oncology indications. Calidi’s off-the shelf universal cell-based delivery platform is designed to protect, amplify and potentiate oncolytic viruses currently in development leading to enhanced efficacy and improved patient safety. Calidi Biotherapeutics is headquartered in San Diego, California. For more information, please visit www.calidibio.com.
DISCLOSURE NOTICE: The information contained in this release is as of January 31, 2020. Calidi assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Forward Looking Statement
Some of the statements in this press release may be forward-looking statements that involve risks and uncertainties inherent in research and development. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. No forward-looking statement can be guaranteed. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control. Calidi Biotherapeutics does not make any representation or warranty, express or implied, as to the completeness or updated status of such statements.
